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Pediatric gastroenterologists, family members, and caregivers of patients with inflammatory bowel disease
(IBD) are on alert; they are all focused on implementing prophylactic measures to prevent infection by severe
acute respiratory syndrome coronavirus 2, evaluating the risks in each patient, guiding them in their treatment,
and keeping IBD in remission.
To face the current issues of the coronavirus disease pandemic, we have developed a synthesis of the main
recommendations of the literature directed at pediatric gastroenterologists in control of patients with pediatric
IBD and adapted to the national reality.
’ INTRODUCTION
In January 2020, a new coronavirus was isolated in humans,
and it was named the novel severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) after an outbreak of pneumonia
of an unknown cause in late 2019 in the city of Wuhan, Hubei
province, China (1).
The disease was called coronavirus disease (COVID-19), a
disease with predominantly respiratory characteristics caused
by SARS-CoV-2: a member of the beta coronaviruses originally
described in bats, similar to the first human SARS coronavirus
and the Middle East Respiratory Syndrome (1).
In March 2020, COVID-19 was declared a pandemic by
the World Health Organization (WHO); it is threatening
global health and destabilizing economies and societies
worldwide (2).
’ TRANSMISSION
SARS-CoV-2 has a high transmission rate, and its most
common means of transmission include person-to-person,
direct contact with contaminated secretions such as saliva
droplets, sneezing, and coughing, and contact with con-
taminated objects or surfaces, followed by touching the mouth,
nose, or eyes (3,4).
The virus was identified in nasopharyngeal and orophar-
yngeal swabs using real-time reverse transcription polymerase
chain reaction (rRT-PCR) in the first cases of COVID-19 in
the United States and in feces using the same method, which
was probably the first identification of SARS-CoV-2 in the
stool of a patient (5).
A published study demonstrated that there is a temporal
difference in the appearance of a positive test depending on
the origin of the samples collected (6). Fecal samples were
positive 2-5 days after detection in respiratory specimens;
additionally, they remained positive for an average of 11 days
after respiratory samples were negative (7).
The viral load required for fecal-oral transmission is not
known yet, but it does not depend on the presence of
diarrhea (7).
The isolation of the virus in stool samples from patients
with COVID-19 proved that SARS-CoV-2 could spread
through feces. Based on its high viral infectivity, it was argued
that exposure to an environment contaminated with feces,
such as public toilets or areas with poor sanitation, could
cause fecal-oral transmission when individuals touched their
mouth, nose, or eyes with contaminated hands (8). Similarly,
the virus could infect healthy family members of patients
via the respiratory route through fecal aerosols caused
by the use of toilet flush when sharing bathrooms (9). This
type of transmission adds a major public health problem to
the environment.
Transplacental or breast milk transmission has not yet
been described; however, maternal-neonatal transmission
shortly after birth has been reported (10).
’ CLINICAL MANIFESTATIONS
Clinical manifestations of COVID-19 include the same
symptoms as those found in other flu-like syndromes, for
example, headache, fever, cough, coryza, odynophagia, myal-
gia, and anorexia (11).
Throughout the evolution of the pandemic and the increase
in case descriptions, diarrhea, vomiting, and anorexiaDOI: 10.6061/clinics/2020/e1962
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(not necessarily associated with respiratory symptoms), were
observed in up to half of the cases of patients with COVID-19,
and in their initial clinical presentations (12,13).
Reports of anosmia are frequent and more specific during
SARS-CoV-2 infection (14).
Most cases of SARS-CoV-2 infection are mild with upper
respiratory symptoms (pharyngeal congestion, sore throat,
and fever) for a short period or even asymptomatic (15).
Moderate illness can manifest with mild pneumonia and
be accompanied by flu-like symptoms without complications
or manifestations related to a serious condition (15).
As COVID-19 progresses to a severe form, in addition to
the flu-like symptoms, there is the occurrence of some of the
following manifestations and laboratory findings: tachypnea,
hypoxia, decreased consciousness, depression, coma, con-
vulsion, dehydration, difficulty with eating, gastrointestinal
dysfunction, myocardial injury, elevation of liver enzymes,
coagulation dysfunction, rhabdomyolysis, and injury to vital
organs. A critical outcome with rapid disease progression
results in the need for support in an intensive care unit (15).
Although fever is a warning sign in this pandemic time of
COVID-19, it is not always present in children (15).
Fortunately, children have a predominantly benign course,
with mild symptoms or even no symptoms, and there is
almost no reported mortality (16,17). However, children may
play a major role in community-based viral transmission,
especially in the home environment (11). The better evolution
of COVID-19 in children is due to a weaker immune
response (11).
Some hypotheses have been discussed to explain the better
clinical evolution of COVID-19 in children, such as the lower
systemic inflammatory response and the release of pro-
inflammatory cytokines; as well as the lower virus concen-
tration in the respiratory tract, probably related to the
difference in the expression of angiotensin-converting enzyme
receptor 2 in the respiratory tract of children than that of
adults (16,17).
’ DIAGNOSIS
According to the Guidelines for the Diagnosis and Treat-
ment of COVID-19 promulgated by the Health Ministry of
Brazil (published on April 6, 2020), the diagnosis of COVID-
19 depends on clinical-epidemiological investigation and
physical examination (18). The Health Ministry recommends
that the laboratory diagnosis of COVID-19 be based on the
rRT-PCR test, which amplifies the RNA sequence of the
virus, enabling its identification. The most frequently used
samples are the nasopharyngeal or oropharyngeal swab (18).
Serological tests for identifying IgM and IgG antibodies
against SARS-CoV-2, which are performed as rapid tests, are
not recommended for the diagnostic confirmation of patients
with symptoms of recent onset, although they have good
diagnostic accuracy in patients with clinical manifestations
lasting more than 8 days (18).
The WHO recommends the following combinations of
laboratory tests for the diagnostic confirmation of SARS-
CoV-2 (19):
a) Confirmed positive PCR for the SARS-CoV-2:
1) at least 2 different clinical specimens (nasopharyngeal
and stool)
2) or the same clinical specimen collected on 2 or more
days during the course of the disease (2 or more
nasopharyngeal aspirates)
3) or 2 different assays or repeated PCR using the origi-
nal clinical sample on each occasion of testing
b) Seroconversion by enzyme-linked immunosorbent assay
or immunofluorescence antibody:
1) negative antibody test on acute serum followed by
positive antibody test on convalescent serum
2) or a four-fold or greater rise in antibody titer between
acute and convalescent phase tested in parallel
The sensitivity of the PCR tests for SARS-CoV-2 depends
on the specimen and the time of testing during the course of
the illness.
It is recommended to obtain a chest X-ray for all patients
with suspected pneumonia. Pediatric patients with COVID-
19 who underwent chest tomography showed fewer changes
and more concentrated lesions in the bronchial walls
compared with adults (20).
However, it is necessary to assess the need for tomography
on a case-by-case basis, especially due to the risk of early
exposure of the child to ionizing radiation.
What is important to know for the care of patients
diagnosed with pediatric IBD during the COVID-
19 pandemic?
Consider that IBD in children tends to be more extensive
and severe than in adults, with a consistently greater need
for immunomodulators and biological agents for them to
remain in remission (21). Despite this, the first cases of
pediatric IBD and SARS-CoV-2 infection described in an
international database for the epidemiological survey on
COVID-19 in children and adults, SECURE-IBD (Surveillance
Epidemiology of Coronavirus Under Research Exclusion) did
not show an unfavorable evolution for children (22).
It was proposed that the use of immunomodulators in
the treatment of IBD patients may block the effects of the
cytokine storm on the inflammatory response of these patients,
leading to the control of inflammation of the bowel mucosa and
prevention of COVID-19 pneumonia (23).
Data collected from the SECURE-IBD platform (22) descri-
bed 704 patients, 9 cases in Brazil until April 22, 2020. There
were cases described (3 cases of children between the ages
of 0-9 years and 28 cases between 10-19 years old) of IBD
associated with COVID-19, but no cases of ICU admission
or death, although 11% of the 10-19 age group required
hospitalization.
In pediatric care, family members and IBD patients have
asked about the risks of SARS-CoV-2 infection, what pre-
cautions to take, and especially how to maintain IBD
treatment, particularly those patients using immunosuppres-
sion. Therefore, in this paper, the implications of SARS-CoV-
2 infection on patients undergoing pediatric IBD treatment
are presented.
1. What are the general procedures and
precautions to be taken during the COVID-19
pandemic in patients with pediatric IBD?
Based on the data available in the literature, individuals
with IBD, with or without immunosuppressive therapy and
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a biological agent, appear to be at no greater risk of
contracting SARS-CoV-2 infection when compared to the
general population (24). Possibly, factors such as the better
adherence of these pediatric patients to protection measures,
supervised by their families, such as hygiene care and social
distance, corroborate this report. In addition, the pediatric
population is less affected by COVID-19 (16).
The procedures to protect and control the spread of the
coronavirus can be summarized (25,26) as described below
(Figure 1):
 Frequent handwashing, with soap and water for at least
20 seconds, especially in a public environment or after
coughing, blowing the nose or sneezing, or after using the
toilet
 If soap and water are not available, hand sanitizer with
a minimum alcohol concentration of 60% may be used,
with attention to cleaning all surfaces of the hands.
Attention should be paid to the use of hand sanitizer,
especially to the risk of domestic accidents, such as burns
in children.
 Avoid touching the eyes, nose, or mouth until hands are
washed.
 Cover the mouth and nose with the back of the elbow
when sneezing or coughing.
 Practice sanitary hygiene and proper disposal of waste.
 With infants, it is necessary to be careful while changing
diapers, properly storing them in waste containers, and
ensuring that they are kept tightly closed.
 Thoroughly launder clothing used outside the home
(in an emergency consultation, going to the clinic or
hospital).
 Cleanse and disinfect surfaces that are touched daily,
including toys, especially if there are flu-like symptoms.
 In children older than 2 years and adolescents with flu-like
symptoms or infected with SARS-CoV-2, the use of a mask
is recommended to reduce viral spread.
 In uninfected children and adolescents, masks should be
worn when away from home.
 Avoid close contact with people affected by COVID-19.
 Maintain a social distance of 1 to 2 meters in public
locations.
Children need to have the supervision of a caregiver
and playful stimulus to follow the hygiene guidelines and
incorporate these procedures into their daily lives. Shared
bathrooms need cleaning and proper garbage disposal,
and small children should not be allowed to access them
unaccompanied.
2. How can I keep consultations for pediatric IBD
during the COVID-19 pandemic?
Face-to-face consultations can be changed to remote visits
(phone, email, video call), reducing patient attendance at
the hospital if not strictly necessary. Exceptions are a relapse
of the disease, exam collection, or infusions. In such cases,
there should be restricted areas for the care of patients with
suspected or diagnosed COVID-19, separate from children
with IBD without SARS-CoV-2 infection (Figure 2). The
use of surgical masks for the health team and for all patients
while they are in the hospital environment should be
maintained (27).
 In all remote consultations, the medical record must be
registered.
 In remote consultation of a stable patient, global guidance
is recommended. Check the general condition of the patient,
the proper use of the prescribed medication, and the main-
tenance of the treatment. Conduct an epidemiological
investigation for COVID-19 in all consultations. In addition
to the general impression of the disease reported by the
patient and/or their family, the patient should perform,
if necessary, inflammatory control tests (C Reactive Protein
and fecal calprotectin) (27).
Figure 1 - General measures and precautions to be taken during the COVID-19 pandemic in pediatric IBD. Modified from Danese et al.
(25) and Turner et al. (26).
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 In remote consultations, uninfected children with IBD
should continue immunosuppressive medications and/
or biological therapy. In cases of acute treatment, face-to-
face assistance is recommended. There is no consensus
regarding the exchange of medications or optimization of
those being used during the pandemic, and therefore, the
determinations must be individualized in each pediatric
gastroenterology service and the decisions shared with the
family.
 In the case of an asymptomatic patient using immunomo-
dulators and a history of home contact with COVID-19, the
rRT-PCR test for SARS-CoV-2 should be requested. If the
test is positive, the medication should be suspended for
two weeks and the immunosuppressive treatment should
only be resumed after two negative tests (28).
 In the remote consultation of a patient with IBD and flu-
like symptoms, it is advised that, in case of fever, cough,
and difficulty breathing, the pediatrician/pediatric gastro-
enterologist should be immediately consulted for face-to-
face evaluation.
 In face-to-face consultations, for patients with fever or
suspected COVID-19, immunosuppressants should be
suspended and local consensus for SARS-CoV-2 infection
should be followed (figure 3). The treatment can be
continued after the complete resolution of symptoms or
ideally after performing 2 nasopharyngeal swab-negative
rRT-PCR tests, collected with an interval of more than 24
hours (28) (Figure 3).
 Sometimes hospitalization may be necessary, due to severe
IBD relapse and more rarely by association with SARS-
CoV-2. COVID-19 does not appear to be a risk factor for
relapses in IBD (29,30).
 Children admitted to the hospital during the pandemic are
allowed to have a companion, but without replacement
during the entire hospital stay.
 During the COVID-19 pandemic, elective endoscopic
examinations should be postponed. The performance of
upper gastrointestinal endoscopy and ileocolonoscopy is
indicated only for potential cases (Cytomegalovirus research)
and emergencies. In exceptional situations, when it is not
possible to postpone the endoscopic procedure, it should
be performed respecting the recommendations published
by the Brazilian Society of Digestive Endoscopy (31).
 Other actions implemented in the various national centers
include facilitating the administration of medicines to
patients (for example, changing the hours of operation of
the pharmacy and increasing the number of doses dis-
pensed). In the case of infusions in a hospital during the
pandemic, it is recommended to pre-screen the symptoms
and temperatures, limit or reduce the number of patients
accessing the infusion room, use masks and gloves (patients
and assistant staff), and maintain appropriate space between
infusion chairs.
In all remote and face-to-face consultations, recommenda-
tions on the prevention of exposure and the practice of social
isolation should be given.
Figure 2 - Remote and face-to-face monitoring of pediatric IBD during the pandemic COVID-19. Modified by Danese et al. (25), Turner
et al. (26), and Fiorino et al. (27).
4
COVID-19 in pediatric inflammatory bowel disease
Fragoso RP and Rodrigues M
CLINICS 2020;75:e1962
3. Can vaccines be administered to pediatric IBD
patients during the COVID-19 pandemic?
 It is important to keep the vaccination card up to date
for all children and adolescents with IBD. During the
COVID-19 pandemic, it is necessary to make sure, mainly,
that vaccines for Influenza and Pneumococcus are carried
out, with the aim of avoiding respiratory complica-
tions that could confuse the diagnosis of COVID-19 (32)
(Figure 4).
4. What are the specific procedures in relation to
each of the medications used by patients with
pediatric IBD during the COVID-19 pandemic?
According to the European Society of Pediatric Gastro-
enterology Hepatology and Nutrition (ESPGHAN), preli-
minary data from IBD in pediatric patients during the
COVID-19 pandemic support the maintenance of standard
IBD treatment, including the use of biological agents, espe-
cially in patients with a more serious disease (26).
In March 2019, recommendations provided by a group of
experts from the International Organization of Inflammatory
Bowel Disease (IOIBD) were described for adults (33). The
IOIBD emphasizes, however, that the recommendations
must be interpreted in the individual context of the patient
with the assistance of their health professionals. They are
not guidelines, and they can be updated as knowledge and
the situation of the pandemic progresses (33). These recom-
mendations may be discussed also in the context of pediatric
IBD care (Figure 5).
Each of the medications used in the treatment of IBD was
evaluated according to the increased risk for SARS-CoV-2
infection and also regarding its suspension in patients infec-
ted with SARS-CoV-2 with or without manifestation of the
disease (Figure 6) (33).
Recommendations for patients undergoing
treatment with 5-aminosalicylic acid (5-ASA) and
sulfasalazine infected with SARS-CoV-2 with or
without manifestation of COVID-19 (33):
 5-ASA does not increase the risk of SARS-CoV-2 infection
or COVID-19.
 Patients on therapy with 5-ASA should not reduce or
discontinue the therapy dose to prevent SARS-CoV-2
infection.
 Patients on therapy with 5-ASA should not interrupt
therapy if they are positive for SARS-CoV-2 with or
without the manifestation of COVID-19.
Figure 3 - Recommendations for pediatric IBD patients with fever during the COVID-19 pandemic. Modified by Mao et al. (29).
Figure 4 - Recommendations on vaccines for pediatric IBD during the COVID 19 pandemic. Modified by Dipasquale & Romano (32).
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Recommendations for patients on treatment with
budesonide infected with SARS-CoV-2 with or
without manifestation of COVID-19 (33):
 Budesonide does not increase the risk of SARS-CoV-2
infection or COVID-19.
 Patients on budesonide therapy should not reduce or
interrupt the dose of therapy to prevent SARS-CoV-2
infection.
 It is uncertain whether patients using budesonide should
discontinue treatment if they are positive for SARS-CoV-2
with or without COVID-19.
Recommendations for patients on treatment with
corticosteroids infected with SARS-CoV-2 with or
without manifestation of COVID19 (33):
 Prednisone (X20 mg/d) increases the risk of infection with
SARS-CoV-2 and COVID-19.
 Patients being treated with prednisone (X20 mg/d) should
reduce the dose of the therapy, if possible, to prevent infec-
tion by SARS-CoV-2.
 Patients on prednisone therapy (X20 mg/d) should dis-
continue therapy (staggered reduction) if they are positive
for SARS-CoV-2 or develop COVID-19.
Figure 5 - Recommendations on medications in patients with pediatric IBD during the pandemic COVID-19. Modified by Danese
et al. (25).
Figure 6 - Recommendations on surgery in patients with pediatric IBD during the COVID-19 pandemic. Modified pandemic by Mao
et al. (29).
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Recommendations for patients undergoing
treatment with azathioprine, 6-mercaptopurine
(6-MP), or methotrexate infected with SARS-CoV-2
with or without manifestation of COVID-19 (33):
 It is uncertain whether azathioprine, 6-MP, or methotre-
xate increases the risk of infection with SARS-CoV-2 or
COVID-19.
 Patients using azathioprine, 6-MP, or methotrexate should
not reduce the dose or discontinue therapy to prevent
SARS-CoV-2 infection.
 Patients using azathioprine, 6-MP, or methotrexate should
discontinue treatment if they are positive for SARS-CoV-2
or develop COVID-19.
Recommendations for patients undergoing
treatment with anti-TNF agents approved by the
National Health Surveillance Agency for pediatric
IBD (infliximab and adalimumab) infected with
SARS-CoV-2 with or without the disease (COVID-
19) (33):
 It is uncertain whether anti-TNF therapy increases the risk
of infection with SARS-CoV-2 or COVID-19.
 Patients on anti-TNF therapy should not reduce the dose
or discontinue therapy to prevent SARS-CoV-2 infection.
According to ESPGHAN recommendations, the exchange
of infliximab for adalimumab should not be encouraged
due to the risk of relapse.
 It is unknown whether patients on anti-TNF therapy
should discontinue therapy if they only show positive
laboratory results for SARS-CoV-2 but have no clinical
manifestation of the disease.
 Patients on anti-TNF therapy should stop the immunobio-
logical if they develop COVID-19.
Patients undergoing combination therapy must be reex-
amined individually. However, currently the interruption of
combination therapy is not a general recommendation for all
cases in the pandemic.
In children, at the moment, it does not seem generally
appropriate to recommend the interruption of immunosup-
pressants in the treatment of patients with pediatric IBD,
except in cases of positive SARS-CoV-2 or COVID-19.
During the COVID-19 pandemic, screening for SARS-CoV-2
is recommended before starting immunosuppressive medica-
tions, to avoid immunosuppression in infected patients.
5. How to manage pediatric IBD patients who need
surgery during the COVID-19 pandemic?
Elective surgeries must be postponed during the COVID-19
pandemic. It is necessary to analyze each patient individually,
to avoid exposing the patient to health risks, and therefore,
in cases of unfavorable evolution, surgical indication may
be necessary (Figure 7).
The Brazilian College of Surgeons published a planning
strategies consensus for urgent/emergency surgeries during
the SARS-CoV-2 pandemic period (34).
It is ideally recommended to screen for COVID-19 in cases
of patients requiring emergency surgery.
6. When to restart immunosuppression of patients
in the postoperative period of IBD during
the pandemic?
There are no published data on prophylaxis for surgical
recurrence during the COVID-19 pandemic. In general, the
choice of medication for prophylaxis of surgical recurrence,
regardless of the pandemic, should be based on patient risk
assessment, but it is always important to ensure that the
patient is not infected with SARS-CoV-2 (35).
’ CONCLUSION
In summary, based on the available data, children have a
predominantly benign course of COVID-19 with IBD, with
mild symptoms and almost no reported mortality.
Figure 7 - Adapted from the recommendations of the International Organization of Inflammatory Bowel Disease (IOIBD) (33).
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Children may play a major role in community-based viral
transmission, especially in the home environment. In infants,
it is necessary to be careful while changing diapers now that
the isolation of the virus in stool samples from patients with
COVID-19 has proven that SARS-CoV-2 can spread through
feces.
Children with IBD, with and without immunosuppressive
and biological therapy, appear to be at no greater risk of
contracting SARS-CoV-2 infection compared to the general
population.
It is considered that IBD in children tends to be more
extensive and severe than in adults with a consistently
higher need for immunomodulators and biological agents for
them to remain in remission.
It may be cautiously suggested that there are currently
no signs indicating a worsening of the COVID-19 course due
to IBD-related treatment. On the other hand, the risk of
inadequate management of IBD caused by the fear of the
virus can have a significant impact on the health of IBD
patients, as indicated by the increase in relapses in those who
have not followed treatment regularly and properly. These
temporary findings may be adjusted in the future based on
emerging data from COVID-19 in children with IBD.
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